Activation syndrome in a patient with attention-deficit/hyperactivity disorder treated with atomoxetine: A case report

Basit Öğe Kaydı
dc.authorid0000-0001-5207-6240en_US
dc.contributor.authorKarakaya, Sümeyra Elif Kaplan
dc.contributor.authorYektaş, Çiğdem
dc.contributor.authorTufan, Ali Evren
dc.date.accessioned2023-06-22T06:23:13Z
dc.date.available2023-06-22T06:23:13Z
dc.date.issued2021en_US
dc.departmentBAİBÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.description.abstractActivation syndrome" represents a cluster of symptoms of excessive emotional arousal or behavioral activation, which emerges after the first few weeks of antidepressant treatment or a dose increase and resolves with dose reduction or cessation of treatment. It was reported after treatment with selective serotonin reuptake inhibitor and serotonin-norepinephrine reuptake inhibitor group of agents, but no case of activation syndrome has been reported with the norepinephrine reuptake inhibitor group. Atomoxetine is a norepinephrine reuptake inhibitor and nonstimulant and is used to manage symptoms of attention-deficit/hyperactivity disorder (ADHD). Atomoxetine-related symptoms of mania and hypomania were reported in literature previously. Here, we report a case of activation syndrome arising after atomoxetine (ATX) dose titration in a prepubertal male child with ADHD. Differentiation of activation symptoms from mania/hypomania symptoms after treatment with ATX may be important for the clinicians to manage the adverse effects and understand the risk factors behind activation syndrome with use of ATX in children and adolescents diagnosed with ADHDen_US
dc.identifier.citationKarakaya, S. E. K., Yektas, Ç., & Tufan, A. E. (2021). Activation Syndrome in a Patient With Attention-Deficit/Hyperactivity Disorder Treated With Atomoxetine: A Case Report. Clinical Neuropharmacology, 44(3), 101-103.en_US
dc.identifier.doi10.1097/WNF.0000000000000447
dc.identifier.endpage103en_US
dc.identifier.issn0362-5664
dc.identifier.issn1537-162X
dc.identifier.issue3en_US
dc.identifier.pmid33661138en_US
dc.identifier.scopus2-s2.0-85106450487en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage101en_US
dc.identifier.urihttp://dx.doi.org/10.1097/WNF.0000000000000447
dc.identifier.urihttps://hdl.handle.net/20.500.12491/11173
dc.identifier.volume44en_US
dc.identifier.wosWOS:000652451000006en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorTufan, Ali Evren
dc.language.isoenen_US
dc.publisherLippincott Williams & Wilkinsen_US
dc.relation.ispartofClinical Neuropharmacologyen_US
dc.relation.publicationcategoryOlgu Sunumu - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAtomoxetineen_US
dc.subjectActivation Syndromeen_US
dc.subjectMood Dysregulationen_US
dc.subjectBipolar Disorderen_US
dc.subjectAdolescentsen_US
dc.subjectChildrenen_US
dc.titleActivation syndrome in a patient with attention-deficit/hyperactivity disorder treated with atomoxetine: A case reporten_US
dc.typeCase Reporten_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Sümeyra-Elif-Kaplan-Karakaya.pdf
Boyut:
94.15 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam metin/Full text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Dahili Tıp Bilimleri Bölümü Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu